Welcome to our dedicated page for Genflow Biosciences news (Ticker: GENFF), a resource for investors and traders seeking the latest updates and insights on Genflow Biosciences stock.
Genflow Biosciences Plc (GENFF) is a UK-headquartered biotechnology company with R&D facilities in Belgium, focused on longevity research and SIRT6-based gene therapies. This news page aggregates regulatory announcements and corporate updates related to Genflow’s scientific programs, intellectual property, and capital markets activity.
Readers can follow developments in Genflow’s gene therapy pipeline, including its 12‑month proof‑of‑concept clinical trial in aged dogs that evaluates a SIRT6‑centenarian gene therapy for age‑related decline. Company updates have highlighted dosing milestones, safety and tolerability observations in elderly dogs, and the design of blinded clinical assessments using biomarkers linked to sarcopenia, healthspan, and lifespan.
The news flow also covers Genflow’s plans to explore GF‑1002 in MASH (Metabolic Dysfunction‑Associated Steatohepatitis), reflecting its interest in metabolic and age‑related disorders. In addition, announcements detail progress in the company’s intellectual property strategy, such as European Patent Office publications recognizing the patentability of SIRT6 variant claims and the publication of a second European patent application titled “SIRT6 Variant for NASH.”
Investors and observers will also find information on equity issues, warrants, and voting rights, including share subscriptions, warrant terms, and total issued share capital figures disclosed for regulatory purposes. Notifications of major holdings and participation in sector events, such as the J.P. Morgan Healthcare Conference, appear in the same stream.
By reviewing the GENFF news page, users can see how Genflow communicates the evolution of its SIRT6 gene therapy platform, its animal health and human-focused programs, and its ongoing regulatory and capital markets disclosures.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) received administrative approval for approximately €4 million in non-dilutive funding from the Wallonia Region to support GF-1002 development for MASH.
First instalment expected no later than May 2026; support covers a three-year programme and makes 2026 priorities capital-efficient, with multiple programme readouts planned.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) appointed Gad Berdugo as Independent Non-Executive Chairman effective immediately, while Tamara Joseph remains on the board to preserve continuity and governance. Mr. Berdugo brings over 30 years of leadership across biotech corporate development, U.S. capital markets and RNA-LNP therapeutics, and currently leads Explorium Capital LLC. The company said his expertise will support advancement of gene-therapy programs, evaluation of delivery technologies, and expanded U.S. engagement. Management highlighted key data readouts expected in 2026. The announcement notes Mr. Berdugo does not own any Genflow shares.
Genflow (OTCQB:GENFF) reported completion of the dosing phase in its blinded canine trial of a SIRT6-based gene therapy on December 16, 2025. All enrolled dogs received full dosing and no adverse events were reported during administration.
Genflow expects a first efficacy read in mid-to-late January 2026 (blood analyses and muscle biopsies) and a second efficacy assessment at the six-month (180-day) timepoint with results expected in June–July 2026. The company plans to resume licensing discussions after efficacy analysis.
Genflow (OTCQB:GENFF) will attend the 44th Annual J.P. Morgan Healthcare Conference on January 12–15, 2026 at the Westin St. Francis in San Francisco.
Participation aims to facilitate meetings with potential partners, institutional investors, and pharmaceutical companies as the company advances its gene‑therapy pipeline targeting the SIRT6 longevity pathway. The appearance is an investor‑relations and business‑development opportunity at a major industry event.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced its total issued share capital and voting rights as at 31 October 2025. The company reported 493,547,942 Ordinary Shares outstanding, with none held in treasury, making the total number of voting rights 493,547,942.
Shareholders may use this figure as the denominator to determine whether they must notify a change in their holding under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Genflow Biosciences (OTC:GENFF) disclosure shows Jonathan Mark Swann increased his holding to 11.32% of voting rights in Genflow Biosciences on 23-Oct-2025, up from 8.40% in the prior notification.
The resulting position equals 55,861,278 voting rights. No financial instruments were reported; the notification lists completion in London on 23-Oct-2025 and states no additional information.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced publication of its second European patent application (Application No. 23821586.7; Publication No. EP4630038) titled “SIRT6 Variant for NASH” in the European Patent Bulletin on October 22, 2025.
The publication follows entry into the European phase under the PCT and provides provisional protection under Article 67(3) EPC, enabling retroactive damages for infringing acts after publication once the patent is granted and national validations are completed. The filing complements the company’s earlier EP4338267 SIRT6 variant application and is presented as part of Genflow’s strategy to expand IP coverage across metabolic and age‑related disorders and support upcoming clinical programs.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced that the European Patent Office published its Euro‑PCT application in the EPO Bulletin on 15 October 2025, recognizing the patentability of claims for a SIRT6 variant patent (EP publication No. EP4338267; application No. 22808414.1; European publication EP4630038).
The publication places the application in the final pre‑grant phase under Article 67(3) EPC and activates provisional protection across participating EPO member states pending national validations. Genflow must bring the description into compliance with the claims in response to an Official Letter before the EPO will issue the intention to grant.
Genflow Biosciences (OTCQB:GENFF) provided an update on its Dog Aging (GF-1004) proof-of-concept trial testing a centenarian SIRT6 gene therapy in elderly dogs.
Repeat administration was completed in October 2025 in the randomized, controlled study of 28 beagles aged 10+, with no ill or adverse effects observed after the second dosing. The dogs enter a follow-up period expected to conclude in January 2026. The company highlighted potential animal-health commercial opportunities and continued partnership development while advancing to next-stage evaluation.
Genflow Biosciences (LSE:GENF / OTCQB:GENFF) announced on 9 October 2025 that it has terminated the previously announced subscription from 2 October 2025 and completed an Alternative Transaction raising gross proceeds of £440,000 via an allotment of 40,000,000 new ordinary shares at 1.1 pence per share. The shares were allotted to CEO Eric Leire, who will direct 35,454,546 shares to a consortium of existing shareholders and retain 4,545,454 shares.
Concurrent warrants will be issued one-for-one, exercisable at 1.2 pence for 24 months. Admission of the new shares is expected on or around 16 October 2025, after which total issued share capital and voting rights will be 493,547,942. The allotment used an employee-offer prospectus exemption under the UK Prospectus Regulation.